Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

(2011) X. C. Badoux et al.   BLOOD

AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells

(2010) A. F. Santidrian et al.   BLOOD

Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia

(2010) Tom Butler et al.   BLOOD REVIEWS

AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies

(2010) Eric Van Den Neste et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Chronic lymphocytic leukemia: planning for an aging population

(2010) John G Gribben   Expert Review of Anticancer Therapy

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53Mutation and Survival in Chronic Lymphocytic Leukemia

(2010) Thorsten Zenz et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Molecular and cellular mechanisms of CLL: novel therapeutic approaches

(2009) Lisa Pleyer et al.   Nature Reviews Clinical Oncology

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

The immunodeficiency of chronic lymphocytic leukaemia

(2008) A. D. Hamblin et al.   BRITISH MEDICAL BULLETIN

Acadesine, an adenosine-regulating agent with the potential for widespread indications

(2008) Brian G Drew et al.   EXPERT OPINION ON PHARMACOTHERAPY

Chronic lymphocytic leukaemia

(2008) G Dighiero et al.   LANCET